Histopathology of human liver biopsies
Patient characteristics by group (sample type based)
early non-alcoholic steatohepatitis (eNASH)
58
female
155
51
yes
gastric bypass
3
2
0
1
50
0
113
73
8
65
42
1.0596135718813846
0.4276990964886409
0.40363686143548044
x
![help](/assets/famfamfam_silk/information-8cfe563be76fb11b27c8ba778f5d40ce6800b244d6ca58ef6e9973308efbe534.png)
Views: 49
Created: 27th Jan 2022 at 22:14
Last updated: 12th Jun 2024 at 13:24
![help](/assets/famfamfam_silk/information-8cfe563be76fb11b27c8ba778f5d40ce6800b244d6ca58ef6e9973308efbe534.png)
This item has not yet been tagged.
![help](/assets/famfamfam_silk/information-8cfe563be76fb11b27c8ba778f5d40ce6800b244d6ca58ef6e9973308efbe534.png)
None
Related items
- People (1)
- Programmes (1)
- Projects (1)
- Investigations (1)
- Studies (1)
- Assays (1)
- Data files (1)
- Sample types (1)
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
One of the tasks of the healthy liver is to store fat. Yet, at some stage, too much fat makes the liver sick. One critical time point occurs when a healthy fatty liver becomes inflamed and progresses to steatohepatitis, or NASH. LiSyM-Pillar I will identify what events lead to this transition. Does it occur in all parts of the liver? Which molecules indicate that it is taking place? Can the degeneration be stopped or undone - and if so, how?
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research/zones-of-the-liver
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
We apply multiphoton imaging, 3D digital reconstructions and computational simulations to generate spatially-resolved geometrical and functional models of human liver tissue at different stages of non-alcoholic fatty liver disease (NAFLD).
Submitter: Fabian Segovia Miranda
Studies: Generation of 3D spatially resolved geometrical and functional models of...
Assays: Experimental assay NAFLD/HO, Experimental assay NAFLD/NC, Experimental assay NAFLD/STEA, Experimental assay NAFLD/eNASH
Snapshots: No snapshots
Histopathological analysis of human biopsies. To quantitatively characterize the transition from simple STEA to eNASH, we stained, imaged and digitally reconstructed human liver tissue in 2D and 3D from biopsies of 25 patients classified into four groups: normal control (NC, n = 6), healthy obese (HO, n = 4), steatosis (STEA, n = 8) and eNASH (n = 7).
Submitter: Fabian Segovia Miranda
Investigation: Three-dimensional spatially resolved geometrica...
Assays: Experimental assay NAFLD/HO, Experimental assay NAFLD/NC, Experimental assay NAFLD/STEA, Experimental assay NAFLD/eNASH
Snapshots: No snapshots
Experimental assay Human-NAFLD/eNASH Samples for the eNASH category were obtained in patients undergoing bariatric surgery with a BMI > 30 and subgroups defined by liver histology as follows: eNASH samples were characterized by >5% fat, an inflammation grade of at least 1, fibrosis ≤1 and ballooning ≤1.
Image data for this assay available via link to file folder containing image data for listed patient IDs (patientID in a file name) ...
Submitter: Olga Krebs
Assay type: Experimental Assay Type
Technology type: Technology Type
Investigation: Three-dimensional spatially resolved geometrica...
Organisms: No organisms
SOPs: No SOPs
Data files: Patient characteristics by group
Snapshots: No snapshots
Patient characteristics by group (sample type based)
Creator: Fabian Segovia Miranda
Submitter: Fabian Segovia Miranda
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Histopathology of human liver biopsies
PAT.ID (String) *, Diagnosis group (Controlled Vocabulary - Diagnostic groups) *, Age (Real number) ( yr ) , Sex (Controlled Vocabulary - Gender) , Weight (kg) (Real number) , BMI (String) , Diabetes Typ II (String) , Surgery indication (String) , Histology: NAS score (Real number) , Histology: NAS fat (Real number) , Histology: NAS balloning (Real number) , Histology: NAS inflammation (Real number) , Fat (Real number) ( % ) , Fibrosis (Real number) , Blood test: GGT (U/l) (Real number) , Blood test: AP (U/l) (Real number) , Blood test: total bilirubin (µmol/l) (Real number) , Blood test: ALT (U/l) (Real number) , Blood test: AST (U/l) (Real number) , Bile acids: primary (µmol/l) (Real number) , Bile acids: secondary (µmol/l) (Real number) , Bile acids: 2º/1º (Real number) , 3D reconstruction (String)
Not specified